Just in time for the holiday season, Lilly unveiled its multi-pronged campaign to tie in Alzheimer’s awareness with cultural ...

Novo Nordisk said this morning that a pair of large, placebo-controlled clinical trials testing an oral version of its GLP-1 ...

Eli Lilly (LLY) rally comes under scrutiny as Novo Nordisk (NVO) readies key late-stage trial results for its GLP-1 pill ...

Eli Lilly has secured marketing authorization from India's CDSCO for its Alzheimer's drug, donanemab. This new ...

GLP-1 drugs like Wegovy and Zepbound have been racking up sales and new indications, as researchers learn more about how the ...

Novo Nordisk’s stock tumbles after its oral GLP-1 drug didn’t show a statistically significant benefit over a placebo against ...

Novo Nordisk's closely watched Alzheimer's trials of an older oral version of its semaglutide drug failed to help slow the ...

Shares of Novo Nordisk plunged after the Danish drug pharmaceutical company said a highly-anticipated trial for Alzheimer's ...

An older oral version of the company's semaglutide drug failed to meet its main goal in late-stage trials testing whether the ...

The studies offer perhaps the most concrete rebuttal yet to an idea that GLP-1 drugs, which have profound benefits on weight ...

In two studies, semaglutide failed to slow decline in thousands of people with early stages of Alzheimer's disease.

The results from the two trials of early-stage Alzheimer's patients, called EVOKE and EVOKE+, are another setback for the ...